Anonymous
Guest
Anonymous
Guest
"AstraZeneca joins the list of drugmakers that have settled with U.S. states over allegations of mismarketing their products. The company agreed to pay $68.5 million to wrap up claims from 37 states and the District of Columbia, which had accused the company of promoting its antipsychotic drug Seroquel for off-label uses such as insomnia and Alzheimer's disease. It's the biggest state settlement with a pharma company on record, Reuters reports."
The deal comes after AZ resolved off-label marketing charges levied by the U.S. Justice Department, agreeing to pay $520 million to settle the case; seven states are still suing.
AstraZeneca has settled another batch of Seroquel liability suits. The drugmaker agreed to pay $150 million to resolve about 6,000 cases claiming AZ knew Seroquel could cause diabetes but didn't adequately warn patients about that risk, sources tell Bloomberg. The deal brings the Seroquel settlement total to almost $350 million.
On average, the latest settlement allocates about $25,000 to each plaintiff, Bloomberg's sources said, more than twice the $11,000 average payout in a $198 million settlement of 17,500 claims last year. That deal, announced last summer, dispensed with some two-thirds of the 26,000 Seroquel claims outstanding in U.S. courts, the company said at the time. Now, with the latest deal, some 4,000 claims are yet to be resolved.
That doesn't mean AZ has admitted to wrongdoing, however. "We deny the allegations," the drugmaker said in a statement. "AstraZeneca believes that it is important to bring these matters to a close and move forward with our business of providing medicines to patients."
Fierce Pharma
$1,000,000,000.00 and continuous Corporate Integrity Agreements. But "we deny the allegations."
The deal comes after AZ resolved off-label marketing charges levied by the U.S. Justice Department, agreeing to pay $520 million to settle the case; seven states are still suing.
AstraZeneca has settled another batch of Seroquel liability suits. The drugmaker agreed to pay $150 million to resolve about 6,000 cases claiming AZ knew Seroquel could cause diabetes but didn't adequately warn patients about that risk, sources tell Bloomberg. The deal brings the Seroquel settlement total to almost $350 million.
On average, the latest settlement allocates about $25,000 to each plaintiff, Bloomberg's sources said, more than twice the $11,000 average payout in a $198 million settlement of 17,500 claims last year. That deal, announced last summer, dispensed with some two-thirds of the 26,000 Seroquel claims outstanding in U.S. courts, the company said at the time. Now, with the latest deal, some 4,000 claims are yet to be resolved.
That doesn't mean AZ has admitted to wrongdoing, however. "We deny the allegations," the drugmaker said in a statement. "AstraZeneca believes that it is important to bring these matters to a close and move forward with our business of providing medicines to patients."
Fierce Pharma
$1,000,000,000.00 and continuous Corporate Integrity Agreements. But "we deny the allegations."